EuropaBio 2026 AGM Appoints New Board Members and Expands Membership

PRESS RELEASE
Brussels, 18 June 2026
EuropaBio’s 2026 Annual General Meeting (AGM), held on 18 June 2026, confirmed the appointment of new Board members and welcomed new association members from across biotechnology ecosystems and international locations. The AGM takes place in EuropaBio’s 30th anniversary year, with 2026 marking three decades since its establishment in 1996.
EuropaBio welcomes the new Board representatives, who will bring leadership from across their respective sectors within biotechnology, and will prove invaluable in guiding the association going forward.
- Hugh Pullen representing Novartis, elected Chair of the Healthcare Biotechnology Council and appointed as a Board Member
- Sabrina Conti representing Merck, elected Vice-Chair of the Healthcare Biotechnology Council
- Frédéric Druck representing bio.be, appointed as a Board Member
- Maciej Gajewski representing Ipsen, appointed as a Board Member
- Lauren Kjeldsen representing Evonik, appointed as a Board Member
- Chris Molloy representing BIA, appointed as a Board Member
- Michael Morrissey representing MSD, appointed as a Board Member
Additionally, 19 new member companies and associations were confirmed during the AGM, further strengthening EuropaBio’s diverse and representative membership across the European biotechnology ecosystem. EuropaBio welcomes Apellis International GmbH, The Baker Company, Biotech Austria, BeneMeat Technologies a.s., Bio-based and Biodegradable Industries Association (BBIA), the Association of Biopharmaceutical Manufacturers in Latvia (BRAL), CrystalsFirst GmbH, Ecolab, European CRO Federation (EUCROF), Grittgene Therapeutics, the Hungarian Biotechnology Association (Magyar Biotechnológiai Szövetség), Luxembourg Institute of Science and Technology (LIST), Nestlé, Niconex Medical Ltd, Pivot Bio, Ribbon Bio GmbH, Slovenia Biotech Hills, Technovative Solutions Limited, and Vial.
Dr Claire Skentelbery, Director General of EuropaBio commented “2026 marks a pivotal year for biotechnology and EuropaBio is at the heart of the EU’s legislative progress. We are delighted our member community continues to grow and diversify, ensuring that all sectors and all actors are part of building its future.”



